Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989.HK)
HKD 4.46
(0.22%)
HKD 4.46
(0.22%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -783.25 Million CNY | -207.68% |
| 2022 | 727.42 Million CNY | 202.1% |
| 2021 | 240.78 Million CNY | -76.49% |
| 2020 | 1.02 Billion CNY | -3.32% |
| 2019 | 1.05 Billion CNY | 71.92% |
| 2018 | 616.19 Million CNY | 369.19% |
| 2017 | 131.33 Million CNY | -66.91% |
| 2016 | 396.89 Million CNY | -31.54% |
| 2015 | 579.77 Million CNY | 71.39% |
| 2014 | 338.27 Million CNY | 6.6% |
| 2013 | 317.33 Million CNY | -49.18% |
| 2012 | 624.39 Million CNY | 0.37% |
| 2011 | 622.08 Million CNY | -48.57% |
| 2010 | 1.2 Billion CNY | 49.5% |
| 2009 | 809.05 Million CNY | 401.3% |
| 2008 | 161.39 Million CNY | 136.78% |
| 2007 | 68.16 Million CNY | 42.35% |
| 2006 | 47.88 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 155.04 Million CNY | 116.74% |
| 2024 Q2 | 508.64 Million CNY | 228.07% |
| 2023 Q3 | 19.82 Million CNY | -65.11% |
| 2023 Q2 | 56.8 Million CNY | -14.62% |
| 2023 Q4 | -926.42 Million CNY | -4774.14% |
| 2023 Q1 | 66.54 Million CNY | -11.07% |
| 2023 FY | -783.25 Million CNY | -207.68% |
| 2022 Q2 | 276.19 Million CNY | 17.56% |
| 2022 Q4 | 74.81 Million CNY | -46.98% |
| 2022 FY | 727.42 Million CNY | 202.1% |
| 2022 Q1 | 234.94 Million CNY | 206.45% |
| 2022 Q3 | 141.11 Million CNY | -48.91% |
| 2021 FY | 240.78 Million CNY | -76.49% |
| 2021 Q1 | 143.48 Million CNY | -54.54% |
| 2021 Q2 | 194.67 Million CNY | 35.68% |
| 2021 Q3 | 123.34 Million CNY | -36.64% |
| 2021 Q4 | -220.71 Million CNY | -278.94% |
| 2020 Q3 | 127.53 Million CNY | -60.85% |
| 2020 Q2 | 325.76 Million CNY | 27.61% |
| 2020 Q1 | 255.29 Million CNY | -34.22% |
| 2020 FY | 1.02 Billion CNY | -3.32% |
| 2020 Q4 | 315.61 Million CNY | 147.47% |
| 2019 Q1 | 507.03 Million CNY | 206.72% |
| 2019 Q2 | 39.36 Million CNY | -92.24% |
| 2019 Q3 | 124.88 Million CNY | 217.21% |
| 2019 Q4 | 388.07 Million CNY | 210.76% |
| 2019 FY | 1.05 Billion CNY | 71.92% |
| 2018 Q1 | 41.98 Million CNY | -46.69% |
| 2018 FY | 616.19 Million CNY | 369.19% |
| 2018 Q2 | 177.1 Million CNY | 321.8% |
| 2018 Q3 | 206.7 Million CNY | 16.71% |
| 2018 Q4 | 165.31 Million CNY | -20.03% |
| 2017 Q4 | 78.76 Million CNY | 74.6% |
| 2017 Q1 | -12.08 Million CNY | -112.98% |
| 2017 FY | 131.33 Million CNY | -66.91% |
| 2017 Q2 | 19.53 Million CNY | 261.67% |
| 2017 Q3 | 45.11 Million CNY | 130.98% |
| 2016 Q4 | 93.08 Million CNY | 117.45% |
| 2016 Q2 | 65.11 Million CNY | -66.76% |
| 2016 Q1 | 195.87 Million CNY | 21.06% |
| 2016 FY | 396.89 Million CNY | -31.54% |
| 2016 Q3 | 42.81 Million CNY | -34.25% |
| 2015 Q4 | 161.8 Million CNY | 13.23% |
| 2015 FY | 579.77 Million CNY | 71.39% |
| 2015 Q3 | 142.89 Million CNY | 59.18% |
| 2015 Q2 | 89.76 Million CNY | -51.56% |
| 2015 Q1 | 185.31 Million CNY | 62.27% |
| 2014 Q3 | 114.05 Million CNY | 192.1% |
| 2014 Q1 | 70.98 Million CNY | 175.62% |
| 2014 Q4 | 114.19 Million CNY | 0.13% |
| 2014 FY | 338.27 Million CNY | 6.6% |
| 2014 Q2 | 39.04 Million CNY | -45.0% |
| 2013 Q4 | 25.75 Million CNY | -37.66% |
| 2013 FY | 317.33 Million CNY | -49.18% |
| 2013 Q1 | 139.1 Million CNY | -3.57% |
| 2013 Q2 | 111.16 Million CNY | -20.09% |
| 2013 Q3 | 41.31 Million CNY | -62.83% |
| 2012 Q3 | 150.45 Million CNY | -3.63% |
| 2012 Q2 | 156.12 Million CNY | -10.04% |
| 2012 FY | 624.39 Million CNY | 0.37% |
| 2012 Q1 | 173.54 Million CNY | 55.12% |
| 2012 Q4 | 144.25 Million CNY | -4.12% |
| 2011 Q3 | 148.09 Million CNY | -29.5% |
| 2011 Q1 | 152.03 Million CNY | -41.43% |
| 2011 FY | 622.08 Million CNY | -48.57% |
| 2011 Q4 | 111.87 Million CNY | -24.46% |
| 2011 Q2 | 210.07 Million CNY | 38.18% |
| 2010 Q1 | 249.7 Million CNY | -27.71% |
| 2010 FY | 1.2 Billion CNY | 49.5% |
| 2010 Q4 | 259.59 Million CNY | -26.11% |
| 2010 Q3 | 351.33 Million CNY | 0.7% |
| 2010 Q2 | 348.87 Million CNY | 39.72% |
| 2009 FY | 809.05 Million CNY | 401.3% |
| 2009 Q1 | 125.16 Million CNY | 0.0% |
| 2009 Q3 | 200.04 Million CNY | 44.52% |
| 2009 Q4 | 345.42 Million CNY | 72.67% |
| 2009 Q2 | 138.42 Million CNY | 10.59% |
| 2008 FY | 161.39 Million CNY | 136.78% |
| 2007 FY | 68.16 Million CNY | 42.35% |
| 2006 FY | 47.88 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 105.03 Million HKD | 845.683% |
| Grand Pharmaceutical Group Limited | 1.87 Billion HKD | 141.663% |
| Extrawell Pharmaceutical Holdings Limited | -162.94 Million HKD | -380.677% |
| Wai Yuen Tong Medicine Holdings Limited | -15.35 Million HKD | -5000.664% |
| Qianhai Health Holdings Limited | -52.7 Million HKD | -1386.117% |
| Lee's Pharmaceutical Holdings Limited | 16.69 Million HKD | 4790.73% |
| Essex Bio-Technology Limited | 275.25 Million HKD | 384.552% |
| Tongfang Kontafarma Holdings Limited | -28.84 Million HKD | -2615.591% |
| PuraPharm Corporation Limited | -106.08 Million HKD | -638.358% |
| SSY Group Limited | 1.31 Billion HKD | 159.4% |
| JBM (Healthcare) Limited | 130.46 Million HKD | 700.368% |
| Jacobson Pharma Corporation Limited | 266.96 Million HKD | 393.39% |
| China Resources Pharmaceutical Group Limited | 3.85 Billion HKD | 120.322% |